On April 18, 2023, the launching ceremony for Maxvax’s production platform for innovative vaccines was successfully held. The ceremony took place in the Life Science & Tech Park of Lingang Special Area, Shanghai. This marks that Maxvax is embarking on a new journey of commercializing its R&D achievements and demonstrates its determination and confidence to promote industrialization.

Maxvax’s CEO Dr. Dexiang Chen started his speech by extending a warm welcome and sincere gratitude to all the government officers, investors and partners present. He said establishing the platform in the Lingang Special Area is part of Maxvax’s strategic move to develop a whole industrial chain from “research and production to sales”. Maxvax aims to build globally leading technology platforms for novel adjuvants and recombinant proteins, develop R&D pipelines for a diversified range of products and expand production capacity constantly, said Dr. Chen. Adopting a two-pronged development strategy and basing itself in the Lingang Special Area Life Science & Tech Park with a global vision, Maxvax works to help China’s vaccines go global, he added.

Mr. Yu Lu, Director of the High-tech Industry and Technology Innovation Division of the Administrative Committee of the Lingang Special Area of Shanghai, delivered a speech. In his speech, he congratulated Maxvax on the official launch of the platform on behalf of the Administrative Committee of the Lingang Special Area. Meanwhile, he said that the Lingang Special Area strives to build the Life Science & Tech Park into a center for the development of the biomedical industry by benchmarking against the international biomedical industrial cluster. He also invited upstream and downstream enterprises of Maxvax to establish businesses in the Lingang Special Area to pursue common development and said that the Lingang Special Area will provide an excellent platform for enterprises to “promote reform and innovation and go global”.

Mr. Linkun Zou, Secretary of the Party Committee and Chairman of Shanghai’s Lingang Fengxian Park, said in his speech that the biomedical industry is one of the three leading industries included in Shanghai’s plan to “build a world-class industrial cluster”. Besides, he also spoke highly of the advantages of the Life Science & Tech Park brought by the strategically important Lingang Special Area and the ecological resources on the north bank of Hangzhou Bay. According to him, Maxvax’s successful launch of the project has had profound contribution to the district’s efforts to expand the scale, improve the capacity and promote cluster development.

Mr. Daqing Cai, General Manager of Sherpa Healthcare Partners, said in his speech that the team of Maxvax has made impressive achievements in the past years and the project launched today is adding another one to its long list of achievements. In the past years, Maxvax has stayed true to its original aspiration, accumulated more experience, strengthened its team, and remained resilient to constant changes in the market, said he. As Maxvax enters a new historical period, he hoped that it will remain focused on innovation and strive to become an industry leader in China and go global to participate in international competition.

Mr. Xiaoyou Zheng from Tofflon which represents the project construction party delivered a speech and congratulated Maxvax on its successful launch of the project. At the same time, he also expressed his hope that the platform will incubate more excellent vaccine products to contribute to the better health of people worldwide and the global public health.

A ribbon-cutting ceremony was held for the successful launch of production platform of innovative vaccines.

Scene of the production center

“On a New Journey towards Delivering Health and Happiness to People through Technological Innovation” - With the official launch of the production center for innovative vaccines, Maxvax will embark on a new journey. Going forward, Maxvax will stay true to its original aspiration, work hard to create a brighter future with technology, promote the high-quality development of China’s vaccines, and build a strong defense line of immunity for human health.